Early neoplastic progression is complement independent.
Infiltration of leukocytes into premalignant tissue is a common feature of many epithelial neoplasms and is thought to contribute to cancer development. However, the molecular and cellular regulatory mechanisms underlying activation of innate host responses to enhanced neoplastic cell proliferation are largely unknown. Considering the importance of the complement system in regulating inflammation during acute pathologic tissue remodeling, we examined the functional significance of complement component 3 (C3) as a regulator of inflammatory cell infiltration and activation during malignant progression by using a transgenic mouse model of multistage epithelial carcinogenesis, e.g., HPV16 mice. Whereas abundant deposition of C3 is a characteristic feature of premalignant hyperplasias and dysplasias coincident with leukocyte infiltration in neoplastic tissue, genetic elimination of C3 neither affects inflammatory cell recruitment toward neoplastic skin nor impacts responding pathways downstream of inflammatory cell activation, e.g., keratinocyte hyperproliferation or angiogenesis. Taken together, these data suggest that complement-independent pathways are critical for leukocyte recruitment into neoplastic tissue and leukocyte-mediated potentiation of tumorigenesis.
de Visser
Karin E
KE
Cancer Research Institute, University of California, San Francisco, 2340 Sutter Street, San Francisco, CA 94143, USA.
Korets
Lidiya V
LV
Coussens
Lisa M
LM
D000818:Animals; D002471:Cell Transformation, Neoplastic; D003176:Complement C3 / Q000378:metabolism*; D005434:Flow Cytometry; D007074:Immunoglobulin G / Q000276:immunology; D007150:Immunohistochemistry; D015603:Keratinocytes / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D009389:Neovascularization, Pathologic / Q000473:pathology; D012878:Skin Neoplasms / Q000276:immunology* / Q000473:pathology*
D003176:Complement C3; D007074:Immunoglobulin G
J Immunol. 2003 Dec 1;171(11):6225-35
14634139
J Exp Med. 1998 Sep 21;188(6):1135-45
9743532
Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1213-7
11700271
Epidemiology. 2001 Jan;12(1):88-93
11138826
BMC Cancer. 2003 Oct 31;3:28
14588079
J Immunol. 2003 Feb 15;170(4):1630-4
12574324
Blood. 1997 Apr 15;89(8):2863-70
9108406
Br J Cancer. 2001 Apr 6;84(7):965-8
11286478
J Exp Med. 2003 Apr 21;197(8):1017-28
12695493
Oncology (Williston Park). 2002 Feb;16(2):217-26, 229; discussion 230-2
11866137
Proc Natl Acad Sci U S A. 1990 Apr;87(8):3230-4
2326280
J Immunol. 1999 Jan 15;162(2):1127-36
9916743
J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67
10469746
J Immunol. 1996 Aug 15;157(4):1693-8
8759757
Cell. 2000 Jan 7;100(1):57-70
10647931
J Virol. 1994 Jul;68(7):4358-68
7515971
J Dermatol. 2000 Mar;27(3):157-62
10774140
Nature. 2002 Dec 19-26;420(6917):860-7
12490959
Am J Pathol. 1996 Dec;149(6):1899-917
8952526
J Immunol. 2002 Oct 1;169(7):3987-92
12244200
Am J Ther. 1995 Oct;2(10):761-767
11854783
Blood. 1990 Aug 15;76(4):655-63
2200535
Digestion. 2001;63 Suppl 1:103-7
11173919
Mol Biol Cell. 1998 Apr;9(4):875-84
9529385
J Immunol. 1999 May 1;162(9):5528-35
10228034
N Engl J Med. 2001 Apr 5;344(14):1058-66
11287977
Gastroenterology. 1990 May;98(5 Pt 1):1264-71
1691118
Cancer Res. 2004 Feb 1;64(3):952-61
14871825
Immunity. 1996 Oct;5(4):387-90
8885871
Proc Natl Acad Sci U S A. 1994 Jan 4;91(1):128-32
8278352
Gut. 1997 Feb;40(2):196-203
9071931
Clin Exp Immunol. 1998 Mar;111(3):484-90
9528887
Immunology. 1975 Jun;28(6):1067-80
48505
Nat Rev Cancer. 2001 Oct;1(1):46-54
11900251
Genes Dev. 1999 Jun 1;13(11):1382-97
10364156
Am J Respir Cell Mol Biol. 2002 Oct;27(4):413-8
12356574
Oncogene. 1999 Dec 20;18(55):7908-16
10630643
J Immunol. 2001 Oct 15;167(8):4141-5
11591733
J Clin Invest. 1993 Nov;92(5):2480-8
7693763
J Immunol. 2000 Nov 15;165(10):5401-5
11067890
Immunol Rev. 2001 Apr;180:35-48
11414361
N Engl J Med. 2001 Apr 12;344(15):1140-4
11297706
Differentiation. 2002 Dec;70(9-10):610-23
12492502
Nature. 1997 Nov 13;390(6656):172-5
9367154
Eur J Immunol. 2001 Nov;31(11):3298-307
11745347
Cell. 2000 Oct 27;103(3):481-90
11081634
Immunity. 1995 Jul;3(1):21-6
7621075
Br J Dermatol. 1998 Nov;139(5):851-4
9892953
Pharmacotherapy. 2002 Mar;22(3):303-9
11898889
J Clin Invest. 1995 Apr;95(4):1539-44
7706459
Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11490-4
8524789
Br J Cancer. 2000 Jul;83(1):112-20
10883678
Annu Rev Microbiol. 2000;54:615-40
11018139
Science. 1994 Aug 19;265(5175):1095-8
8066448
Nat Rev Immunol. 2002 Oct;2(10):773-86
12360215